MAP2K7 and atypical chronic myeloid leukemia, BCR-ABL1 negative: Moreover, MEK inhibitors (e.g., trametinib) and SRC kinase inhibitors (e.g., dasatinib) have been evaluated in prospective clinical trials for patients with aCML [19].